ECOSYSTEM TOUR OPTIONS
NSG BioLabs
NSG opened in November 2019 with the support of Singapore’s Ministry of Trade and Industry (Enterprise Singapore) and is located in the heart of Biopolis, Singapore’s main biomedical research centre. NSG is Singapore’s largest and only BSL2 certified co-working laboratory and office provider and has four fully-equipped laboratory facilities. It has over 400 available laboratory equipment for shared use, designated shared rooms for cell culture, private lab rooms, tissue culture facilities, chemical hoods, microbiological and pre-PCR rooms across 4 laboratory sites. NSG provides flexible options for companies to start research immediately, and then incrementally grow over time.
As the only BSL-2 and fully HEPA filtered co-working laboratories in Singapore, NSG has been the location of choice for many biotech companies and large multinational companies with high standards for laboratory space. Large companies that have set up R&D operations in NSG include Applied Materials, Oxford Nanopore Technologies, L’Oreal, MGI, and Crown Bioscience (subsidiary of JSR Life Sciences). We also have exciting biotech startups from MIT, Harvard, Duke-NUS, A*STAR, and others that have received close to $400m of funding from top-tier global investors.
Nucleic Acid Therapeutics Initiative (NATi)
The Nucleic Acid Therapeutics Initiative (NATi) is a National Platform with the mission to build Singapore up as the regional hub and model of excellence for research and clinical translation, and commercialisation of nucleic acid therapeutics (NAT) with built-in preparedness and resilience against future epidemics. Hosted by the Agency for Science, Technology and Research (A*STAR), NATi works collaboratively with public sector and industry partners to accelerate the translation and commercialisation of RNA assets, while strengthening resilience. Learn more here: www.a-star.edu.sg/NATi
Experimental Drug Development Centre (EDDC)
EDDC translates great science to great medicines through our industry-level, highthroughput and computationally augmented drug discovery and development capabilities. We focus on addressing diseases with high unmet need and global impact. By working with universities, research institutes and healthcare institutions across Singapore, and around the world, we enable the development of new and impactful therapeutics. We also nurture the biotech scene in Singapore, and work with biopharmaceutical companies to advance our
portfolio assets.
EDDC has a full and comprehensive suite of capabilities for small and large molecule discovery through to preclinical and clinical development. Over the past decade, we have established a strong track record of advancing first- and best-in-class therapeutic assets from discovery into clinical development, including two oncology small molecules and one antibody-drug conjugate. EDDC has completed multiple licensing agreements, including a preclinical oncology deal with a major pharmaceutical company.
